Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (SEHK: 1349)
Health Care · Pharmaceuticals · CN
HK$2.59
-0.96% today · -34.3% 1Y
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (SEHK: 1349) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.02B and employs 876 people.
Over the last twelve months the share price has lost 34.3%, trading between 2.20 and 4.05.
Tweenvest scores Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. across four factors: quality 68/100, value 60/100, growth 0/100. Its strongest factor is quality.
1349 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.02B
- Revenue (TTM)
- $98.33M
- P/E
- —
- EPS
- -0.12
- Dividend yield
- —
- Beta (5Y)
- 0.09
- 52-week high
- HK$4.05
- 52-week low
- HK$2.20
- Avg volume (3M)
- —
- Shares outstanding
- 1.04B
- Employees
- 876
- Next earnings
- —
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., along with its affiliated entities, is dedicated to the research, development, production, and commercialization of biopharmaceutical products. The company leverages its genetic engineering platform to advance antibody-drug conjugates (ADCs), including CD30-DM1 ADC and Trop2-SN38 ADC, both in Phase I clinical trials for various tumors. Trop2-BB05 ADC is undergoing preclinical evaluation for lung and triple-negative breast cancers, while HER2 ADC has completed preclinical studies for metastatic breast and gastric cancers. Furthermore, Fudan-Zhangjiang utilizes its photodynamic technology platform, featuring hemoporfin in Phase IV clinical trials for port-wine stains, and aminolevulinic acid, which is progressing through Phase II trials for HPV-related cervical conditions and acne, having also finished preclinical investigation for brain gliomas. Its nanotechnology platform is advancing drugs like Nanoparticle Albumin-bound Paclitaxel, undergoing preclinical assessment for oncological applications, and Doxorubicin liposome, also under development for tumors. The firm's expertise in oral solid preparations encompasses obeticholic acid for hepatobiliary and autoimmune disorders; timolol maleate cream, currently in preclinical studies for infantile hemangioma; and the oral formulation FZJ-003, which is in Phase I clinical trials for rheumatoid arthritis and Phase II for atopic dermatitis and ulcerative colitis. Beyond pharmaceuticals, the company is involved in developing both pharmaceutical and medical devices, as well as medical diagnostic solutions and associated services. It also markets everyday consumer goods, clinical laboratory analysis equipment, and relevant software. Additional activities include technology innovation, licensing, consultancy, and promotional efforts, alongside the manufacturing of lyophilized powder injections and active pharmaceutical ingredients (APIs). The company also allocates capital to international medical ventures. Established in 1996, the company operates from its headquarters in Shanghai, People's Republic of China.
- ISIN
- CNE1000000W4
- Founded
- 1996
- Listed since
- Aug 13, 2002
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.